MedTech Dive is rounding up medtech companies' preliminary earnings and related news during the week of the J.P. Morgan Healthcare Conference. Please check back for updates.
Heart pump maker Abiomed said in its pre-release that certain presentations at the American Heart Association's Scientific Sessions conference in November were based on "misleading analyses" and hurt its performance during the fiscal third quarter of 2020. Abiomed's stock was down more than 17% in early trading Monday.
The company said it's taking a number of actions, including beginning a road show during its fourth quarter "to review with physicians Impella's current clinical data, FDA studies and best practices that support Impella's indications for high-risk PCI, cardiogenic shock and right heart failure."
Results: Revenues during the quarter rose 10% to $221.6 million, below the $229 million modeled by investment firm Jefferies.
Outlook: Abiomed updated its fiscal year 2020 revenue guidance to the range of $846 million to $877 million, which would represent growth between 10% and 14%.
Abiomed is slated to present at JPM on Monday.
Baxter said its operational sales growth during the fourth quarter is its best since the 2015 spin-off of biopharmaceutical division Baxalta. The company did not offer further detail on its internal accounting investigation, but said it expects to report complete third quarter, fourth quarter and full-year results no later than the end of the first quarter of 2020.
Results: Q4 sales up 7% as reported to more than $3 billion (approximately $1.3 billion in the U.S. and $1.8 billion internationally); beat consensus expectations by about $100 million, according to investment firm Stifel. Full year sales are expected to be up 2% as reported to $11.4 billion.
Outlook: Baxter expects full-year 2020 sales to grow 4% to 5% as reported (not taking into account the planned $350 million acquisition of Sanofi's SepraFilm, expected to close during the first quarter). The company said its next earnings presentation will provide further details and outline its cash flow expectations for 2020.
Baxter is set to present at JPM on Monday.
Boston Scientific missed Wall Street's fourth quarter revenue growth expectations, per preliminary results shared Tuesday morning, with shares down about 6.5% in premarket trading. "It appears that [Boston Scientific's cardiac rhythm management] business was the largest contributor to the 4Q19 shortfall," Needham analysts wrote in a note to investors, adding that it's not yet clear whether Boston lost share or if the broader market slowed during the quarter.
Results: Fourth quarter sales of $2.90 billion were up 13.4% as reported, toward the lower end of the company's anticipated growth of 13% to 15%). On an organic basis, sales grew 7.3%, missing the company's 8% to 9% guidance range. For the full year 2019, sales grew 9.3% as reported (the midpoint of its guidance) to total $10.74 billion, again missing the organic growth target (7.3% vs. 7.5%).
Outlook: Boston Scientific will provide first quarter and full year guidance on its Feb. 5 earnings call before the markets open.
Boston Scientific is scheduled to present Tuesday at JPM.
Dexcom's quarterly results topped the consensus estimate by around $25 million, according to analysts at Cowen.
Results: Fourth quarter revenues from 2019 rose 35% as reported to roughly $457 million, with U.S. revenue growing 33% to $373 million and the international segment increasing 47% to $84 million. On the year, Dexcom said its total revenue came to approximately $1.47 billion, up 42% compared to 2018.
Outlook: Dexcom predicts 2020 revenues between $1.725 billion and $1.775, or 17% to 21% growth over 2019. The company said it will elaborate further on its Feb. 13 earnings call. "Much like recent years, we suspect this first-pass guidance could prove conservative," analysts at Stifel wrote in a note to investors.
Dexcom plans to present at JPM on Monday.
Shares in Exact Sciences were down more than 11% in early trading Monday after the company reported 2019 earnings figures Sunday. Wall Street analysts largely lauded the results, calling them mostly in-line, if short of a blowout, finish to the year.
Results: Fourth quarter revenues from 2019 are between $294 million and $296 million, with Cologuard test volume up 63% over 2018, and recently acquired Genomic Health's Oncotype DX's test volume up 14%. Full year revenues are expected to be between $874.5 million and $876.5 million, with 1.68 million Cologuard tests sold in 2019.
Outlook: The company plans to offer guidance for 2020 during a February earnings call.
Exact Sciences is scheduled to present at JPM on Wednesday.
Hologic edged out the high end of its most recent revenue guidance for the fourth quarter on continued strength in its core diagnostics and breast health businesses. "Upside in Surgical and Diagnostics, combined with revenue from SuperSonic Imagine, more than offset weakness in our divested Medical Aesthetics business," CEO Steve MacMillan said in a statement.
Results: Revenues for the fiscal first quarter grew 2.4% to $850.5 million (or excluding M&A activity, up 4.1%).
Outlook: Hologic announced Sunday a new $500 million share repurchase authorization set to take effect at the start of its fiscal third quarter. The company offered fiscal 2020 revenue guidance of $3.45 billion to $3.50 billion when it last reported earnings in November.
Hologic's investor presentation at JPM is happening Monday.
NuVasive saw its biggest U.S. revenue bump in spinal hardware, up about 8% on the quarter and 7% on the year. International revenues were up 14% during the quarter and 10% on the year.
Results: Fourth quarter revenues grew 8% as reported to $310 million, compared to a consensus estimate of about $304 million, according to Seeking Alpha. Full year revenues are expected to be up 6% as reported to approximately $1.17 billion.
Outlook: NuVasive said it will provide its 2020 financial forecast on a yet-to-be-scheduled earnings call in late February.
NuVasive is set to present at JPM on Wednesday.
Other medtechs reporting preliminary earnings
Atricure, Axonics, Conformis, GenMark Diagnostics, Globus Medical, Inogen, Integra LifeSciences, Intersect ENT, Intuitive Surgical, Invitae, Masimo, NanoString, Natus Medical, Nevro, Novocure, OrthoPediatrics, RTI Surgical, Sientra, STAAR Surgical and ViewRay.
This piece has been updated to include preliminary results shared by Boston Scientific and additions to the growing group of companies releasing earnings numbers (see running list at bottom).